帕姆雷单抗治疗特发性肺纤维化:ZEPHYRUS-1随机临床试验
这项3期随机临床试验纳入356例未接受抗纤维化治疗的特发性肺纤维化患者,评估帕姆雷单抗(30 mg/kg静脉注射,每3周一次)与安慰剂的疗效和安全性。结果显示,第48周时两组用力肺活量(FVC)自基线的绝对变化无显著组间差异(最小二乘均值,帕姆雷单抗组-260 mL vs 安慰剂组-330 mL;组间均值差70 mL,95%CI -60至190 mL,P=0.29),所有次要结局和患者报告结局均无显著组间差异。
要点
- 帕姆雷单抗组与安慰剂组第48周FVC自基线绝对变化无显著组间差异(组间均值差70 mL,95%CI -60至190 mL,P=0.29)。
- 所有次要结局及患者报告结局均无显著组间差异。
- 治疗相关不良事件:帕姆雷单抗组160例(88.4%)vs 安慰剂组151例(86.3%);严重不良事件:帕姆雷单抗组51例(28.2%)vs 安慰剂组60例(34.3%)。
核心结论
- 在特发性肺纤维化患者中,帕姆雷单抗与安慰剂相比,主要结局第48周FVC自基线绝对变化无统计学显著组间差异。
研究设计与样本
- 3期随机临床试验,纳入356例年龄40至85岁、入组时未接受尼达尼布或吡非尼酮抗纤维化治疗的特发性肺纤维化患者。
- 患者于2019年7月18日至2022年7月29日期间从9个国家117个中心招募,末次随访发生于2023年8月28日。
- 干预为帕姆雷单抗30 mg/kg静脉注射每3周一次(n=181)或安慰剂(n=175),疗程48周。
主要发现
- 第48周FVC自基线绝对变化的最小二乘均值:帕姆雷单抗组-260 mL(95%CI -350至-170 mL)vs 安慰剂组-330 mL(95%CI -430至-230 mL);组间均值差70 mL(95%CI -60至190 mL),P=0.29。
- 所有次要结局及患者报告结局均无显著组间差异。
- 治疗相关不良事件:帕姆雷单抗组160例(88.4%)vs 安慰剂组151例(86.3%);严重不良事件:帕姆雷单抗组51例(28.2%)vs 安慰剂组60例(34.3%)。
- 死亡:帕姆雷单抗组23例(12.7%)vs 安慰剂组23例(13.1%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Current treatments for idiopathic pulmonary fibrosis slow the rate of lung function decline, but may be associated with adverse events that affect medication adherence. In phase 2 trials, pamrevlumab (a fully human monoclonal antibody that binds to and inhibits connective tissue growth factor activity) attenuated the progression of idiopathic pulmonary fibrosis without substantial adverse events. OBJECTIVE: To assess the efficacy and safety of pamrevlumab for patients with idiopathic pulmonary fibrosis. DESIGN, SETTING, AND PARTICIPANTS: Phase 3 randomized clinical trial including 356 patients aged 40 to 85 years with idiopathic pulmonary fibrosis who were not receiving antifibrotic treatment with nintedanib or pirfenidone at enrollment. Patients were recruited from 117 sites in 9 countries between July 18, 2019, and July 29, 2022; the last follow-up encounter occurred on August 28, 2023. INTERVENTIONS: Pamrevlumab (30 mg/kg administered intravenously every 3 weeks; n = 181) or placebo (n = 175) for 48 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was absolute change in forced vital capacity (FVC) from baseline to week 48. There were 5 secondary outcomes (including time to disease progression, which was defined as a decline of ≥10% in predicted FVC or death). The exploratory outcomes included patient-reported symptoms. Adverse events were reported. RESULTS: Among 356 patients (mean age, 70.5 years; 258 [72.5%] were men; 221 [62.1%] were White), 277 (77.8%) completed the trial. There was no significant between-group difference for absolute change in FVC from baseline to week 48 (least-squares mean, -260 mL [95% CI, -350 to -170 mL] in the pamrevlumab group vs -330 mL [95% CI, -430 to -230 mL] in the placebo group; mean between-group difference, 70 mL [95% CI, -60 to 190 mL], P = .29). There were no significant between-group differences in any of the secondary outcomes or in the patient-reported outcomes. In the pamrevlumab group, there were 160 patients (88.4%) with treatment-related adverse events and 51 patients (28.2%) with serious adverse events vs 151 (86.3%) and 60 (34.3%), respectively, in the placebo group. During the study, 23 patients died in each group (12.7% in the pamrevlumab group vs 13.1% in the placebo group). CONCLUSIONS AND RELEVANCE: Among patients with idiopathic pulmonary fibrosis treated with pamrevlumab or placebo, there was no statistically significant between-group difference for the primary outcome of absolute change in FVC from baseline to week 48. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03955146.
引用
- Raghu G, Richeldi L, Fernández Pérez ER, et al. Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial. JAMA. 2024. PMID: 38762797. doi:10.1001/jama.2024.8693
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。